➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: October 23, 2021

DrugPatentWatch Database Preview

Claims for Patent: 8,118,771

Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,118,771
Title:Needleless injector drug capsule and a method for filling thereof
Abstract: A method for filling needleless injector capsules with liquid drug, whereby dissolved gas within the drug is replaced by a less soluble gas in order to reduce the inclusion of gas bubbles, or to prevent the growth of bubbles during storage and thereby prevent breakage of the capsules.
Inventor(s): Henry; William (Trumpington, GB), Lewis; Andrew (Trumpington, GB)
Assignee: Zogenix, Inc. (Emeryville, CA)
Application Number:11/926,608
Patent Claims: 1. A method of reducing breakage of a needle-free injector drug capsule, comprising: preventing growth of bubbles in a liquid drug during storage by sparging the liquid drug with an inert gas having a solubility of 0.5 cm.sup.3 to 25 cm.sup.3 in 100 cm.sup.3 of the liquid drug to obtain a sparged liquid drug; loading the sparged liquid drug into a glass capsule strengthened with ion exchange; and storing the capsule.

2. The method of claim 1, wherein prior to loading the liquid drug into the capsule the capsule is evacuated to about 0.5 mbar.

3. The method as claimed in claim 1, further comprising: sealing the capsule in an atmosphere of the inert gas prior to loading the capsule.

4. The method as claimed in claim 1, wherein the inert gas is selected from the group consisting of helium, argon, neon, krypton, xenon, nitrogen, a chlorofluorocarbon, a hydrofluorocarbon, and a mixture thereof.

5. The method as claimed in claim 1, wherein the inert gas does not comprise helium.

6. The method as claimed in claim 1, wherein the inert gas comprises helium.

7. The method as claimed in claim 1, wherein the liquid drug is chosen from: a solution, and a suspension.

8. The method as claimed in claim 1, further comprising: forcing the inert gas through a filter comprising apertures of not more than 0.2 .mu.m prior to contacting the gas with the liquid drug.

9. The method as claimed in claim 1, wherein bubbles are prevented from growing above 2 .mu.l in volume.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.